Anzeige
Erschienen in:
08.01.2021 | Original Research
A National Survey on Patient Provider Agreements When Prescribing Opioids for Chronic Pain
Erschienen in: Journal of General Internal Medicine | Ausgabe 3/2021
Einloggen, um Zugang zu erhaltenAbstract
Background
Many national guidelines recommend the use of patient provider agreements (PPAs) when prescribing opioids for chronic pain. There are no standards for PPA content, readability, or administration processes.
Objective
Conduct a national survey of providers who use PPAs to describe the process of administering them, assess views on their utility, and obtain PPAs to evaluate thematic content and readability.
Design
Cross-sectional electronic survey and request for PPAs.
Participants
Registrants for the Safer/Competent Opioid Prescribing Education (SCOPE of Pain) Program between March 2013 and June 2017.
Main Measures
Respondents’ reports on how PPAs are administered and views on their usefulness. A sample of PPAs assessed for themes and readability.
Key Results
Using a convenience sample of 62,530 SCOPE of Pain registrants, we obtained a cohort of 430 individuals from 43 states who use PPAs. The majority of respondents worked in primary care (64%) and pain (18%) specialties. Reviewing PPAs with patients was primarily done by prescribers (80%), and the average perceived time to administer PPAs was 13 min. Although 66% of respondents thought PPAs were “often” or “always” worth the effort, only 28% considered them “often” or “always” effective in reducing opioid misuse. The PPA reading burden surpassed recommended patient education standards, with only 2.5% at or below fifth-grade reading level. PPAs focused more on rules and consequences of patients’ non-compliance than on a shared treatment plan.
Conclusions
Most respondents perceive patient provider agreements (PPAs) as time-consuming and minimally effective in reducing opioid misuse yet still view them as valuable. PPAs are written far above recommended reading levels and serve primarily to convey consequences of non-compliance. Because PPAs are recommended by national safer opioid prescribing guidelines as a risk mitigation strategy, it would be beneficial to develop a standard PPA and study its effectiveness.